Literature DB >> 15191165

Reassessment of caspase inhibition to augment grafted dopamine neuron survival.

Deanna M Marchionini1, Timothy J Collier, Mark R Pitzer, Caryl E Sortwell.   

Abstract

One experimental therapy for Parkinson's disease (PD) is the transplantation of embryonic ventral mesencephalic tissue. Unfortunately, up to 95% of grafted neurons die, many via apoptosis. Activated caspases play a key role in execution of the apoptotic pathway; therefore, exposure to caspase inhibitors may provide an effective intervention strategy for protection against apoptotic cell death. In the present study we examined the efficacy of two different caspase inhibitors, caspase-1 inhibitor Ac-YVAD-CMK and caspase-3 inhibitor Ac-DEVD-CMK, to augment mesencephalic tyrosine hydroxylase-immunoreactive (TH-ir) neuron survival in culture and following implantation into the denervated striatum of rats. We report that treatment with Ac-YVAD-CMK provided partial but nonsignificant protection for TH-ir neurons against serum withdrawal in mesencephalic cultures plated at low density, while neither caspase inhibitor promoted TH-ir neuron survival in higher density cultures, simulating graft density. We demonstrate that plating procedures (full well vs. microislands) and cell density directly affect the degree of insult experienced by TH-ir neurons following serum withdrawal. This varying degree of insult directly impacts whether caspase inhibition will augment TH-ir neuron survival. Our grafting experiments demonstrate that Ac-YVAD-CMK does not augment grafted TH-ir neuron survival when added to mesencephalic cell suspensions prior to grafting or to mesencephalic reaggregates for 3 days in vitro prior to transplantation. These experiments provide further evidence of the failure of these caspase inhibitors to augment TH-ir neuron survival. Furthermore, we suggest that cell culture paradigms used to model grafting paradigms must more closely approximate the cell densities of mesencephalic grafts to effectively screen potential augmentative treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191165     DOI: 10.3727/000000004783983972

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  6 in total

Review 1.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

Review 2.  Ion channels in regulation of neuronal regenerative activities.

Authors:  Dongdong Chen; Shan Ping Yu; Ling Wei
Journal:  Transl Stroke Res       Date:  2014-01-08       Impact factor: 6.829

3.  Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α.

Authors:  J Chou; N H Greig; D Reiner; B J Hoffer; Y Wang
Journal:  Cell Transplant       Date:  2011-02-03       Impact factor: 4.064

4.  Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury.

Authors:  Juan Pablo de Rivero Vaccari; George Lotocki; Ofelia F Alonso; Helen M Bramlett; W Dalton Dietrich; Robert W Keane
Journal:  J Cereb Blood Flow Metab       Date:  2009-04-29       Impact factor: 6.200

5.  Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons.

Authors:  Brian T Terpstra; Timothy J Collier; Deanna M Marchionini; Nathan D Levine; Katrina L Paumier; Caryl E Sortwell
Journal:  J Neurosci Methods       Date:  2007-07-01       Impact factor: 2.390

6.  Intra-cerebral implantation of a variety of collagenous scaffolds with nervous embryonic cells.

Authors:  Jacek Drobnik; Krystyna Pietrucha; Karolina Janczar; Lech Polis; Bartosz Polis; Marta Safandowska; Jacek Szymański
Journal:  Exp Ther Med       Date:  2019-10-21       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.